{"entity":{"id":"nct01974661","kind":"trial","name":"Phase I Safety Study of Dendritic Cell Vaccine to Treat Patients With Hepatocellular Carcinoma","aka":[],"tldr":"A phase 1 trial of Ilixadencel run by Mendus, completed.","summary":"Phase I Safety Study of Dendritic Cell Vaccine to Treat Patients With Hepatocellular Carcinoma is a phase 1 interventional study registered as NCT01974661 by Mendus, with 18 participants enrolled, started 2013-10. Conditions recorded: Hepatocellular Carcinoma. Interventions recorded: COMBIG-DC (ilixadencel).","status":"completed","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT01974661","url":"https://clinicaltrials.gov/study/NCT01974661"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":["ilixadencel"],"companies":["mendus"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01974661","phase":"1","setting":"A Phase I Open-label Study to Evaluate Safety and Immunologic Response of COMBIG-DC Administered Intra-tumorally in Patients With Hepatocellular Carcinoma","sponsor":"Mendus","enrolled":18,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct01974661/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"drug":[{"id":"ilixadencel","kind":"drug","name":"Ilixadencel","route":"/drugs/ilixadencel/"}],"company":[{"id":"mendus","kind":"company","name":"Mendus","route":"/companies/mendus/"}]}}